MWB lifted DrÀgerwerk target to EUR 130: DrÀgerwerk stock gains 2.51 percent
Published on 10/09/2026 at 14:07 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWSKey points in brief
- MWB Research lifted its DrÀgerwerk price target to EUR 130.00 on September 10, 2026.
- Second-quarter revenue rose 8.60 percent year over year to EUR 847.30 million.
- DrÀgerwerk stock was trading at EUR 114.40 at Lang & Schwarz on October 9, 2026, plus 2.51 percent versus the prior close.
- DrÀgerwerk expects a 2026 EBIT margin of 5.00 to 7.50 percent, with third-quarter results scheduled for October 29, 2026.
DrÀgerwerk (ISIN DE0005550636) was trading at EUR 114.40 at Lang & Schwarz on October 9, 2026 at 2:03 p.m. CEST, up 2.51 percent versus the EUR 111.60 prior close. On September 10, 2026, MWB Research had lifted its DrÀgerwerk price target to EUR 130.00, citing stronger confidence in margin development, as wallstreetONLINE reported.
Revenue and profit improved
DrÀgerwerk reported second-quarter 2026 revenue of EUR 847.30 million, an 8.60 percent increase from EUR 779.99 million in the year-earlier quarter. Net income rose to EUR 29.52 million from EUR 11.26 million, a 162.10 percent increase, according to aktienmagazin.de.
The figures point to a sharper earnings recovery than the sales increase alone suggests. Net margin reached 3.49 percent in the second quarter of 2026, compared with 1.44 percent in the second quarter of 2025, calculated from the reported revenue and net income figures.
What does the margin outlook show?
DrÀger's Investor Relations page gives a 2026 EBIT margin outlook of 5.00 to 7.50 percent, alongside currency-adjusted revenue growth of 2.00 to 6.00 percent. The company also expects DVA between EUR 20.00 million and EUR 120.00 million in fiscal year 2026, according to its Investor Relations page.
Three milestones frame the recovery
On March 24, 2026, DrÀger reported fiscal 2025 revenue of EUR 3.50 billion after revenue of EUR 3.40 billion in fiscal 2024, as listed in the company's news record at finanzen.ch. On July 30, 2026, the second-quarter revenue reached EUR 847.30 million and net income EUR 29.52 million. The September 10, 2026 MWB target of EUR 130.00 then set a higher valuation reference.
Next reporting date is October 29
DrÀgerwerk's next scheduled reporting date is October 29, 2026, for third-quarter results, according to MarketScreener. That release will help test whether the second-quarter margin improvement is carrying into the second half.
Stock gains with target above market
At Lang & Schwarz, DrÀgerwerk stock was trading at EUR 114.40 on October 9, 2026 at 2:03 p.m. CEST, up 2.51 percent from the EUR 111.60 prior close. The quote remained EUR 15.60 below the MWB target of EUR 130.00, although the two figures represent a market price and an analyst valuation reference rather than the same trading venue.
The further course of trading is shown by the continuously updated real-time quote of DrÀgerwerk stock.
DrÀgerwerk stock at a glance
- Company: DrÀgerwerk AG & Co. KGaA
- ISIN: DE0005550636
- Ticker: DRW3.DE
- Price Lang & Schwarz (as of October 9, 2026, 2:03 p.m. CEST): EUR 114.40
- Change versus prior close: plus 2.51 percent
- Prior close Lang & Schwarz (October 8, 2026): EUR 111.60
- Market capitalization: EUR 2.1 billion (as of October 9, 2026)
- 52-week range: EUR 64.90-EUR 125.40 (as of October 9, 2026)
- Sector / Industry: Health care equipment and medical and safety technology
- Index membership: TecDAX
- Next earnings date: October 29, 2026
Market context: Market report DAX.
